Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hra pharma rare diseases sas (8191301) - metyrapon - weichkapsel - teil 1 - weichkapsel; metyrapon (07640) 250 milligramm

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - levocetirizin dihydrochlorid -

Europäische Union - Deutsch - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kann als monotherapie oder in kombination mit methotrexat verwendet werden. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Europäische Union - Deutsch - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunsuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ucb pharma gmbh - levocetirizin dihydrochlorid - levocetirizin

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

genericon pharma gmbh - levocetirizin dihydrochlorid - levocetirizin

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

actavis group ptc ehf. - levocetirizin dihydrochlorid - levocetirizin

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

synthon bv - levocetirizin dihydrochlorid - levocetirizin

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

stada arzneimittel gmbh - levocetirizin dihydrochlorid - levocetirizin